
    
      To collect safety data while providing drotrecogin alfa (activated) for the treatment of
      patients with severe sepsis with multiple organ dysfunctions. Patient access to drotrecogin
      alfa (activated) will be provided under this protocol prior to and during its review by the
      Authorities of Belgium and Luxemburg for commercial release.
    
  